Three and one-half years' experience with a lower-dose combination oral contraceptive.
Updated data are presented that span 43 cycles of use of norgestrel 0.030 mg as a lower-dose combination oral contraceptive. Active participation by 1,633 women in 20,312 treatment cycles has resulted in a use-effectiveness rate of 0.13 per 100 woman-years. Satisfactory cycle control, minimal menstrual irregularities and a low incidence of side effects produced high acceptability among users. No drug toxicity was demonstrated. The incidence of discontinuance for medical reasons was low.
D000293:Adolescent; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003276:Contraceptives, Oral / Q000008:administration & dosage*; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D008598:Menstruation / Q000187:drug effects; D009644:Norgestrel / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D010352:Patient Dropouts
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D009644:Norgestrel; D004997:Ethinyl Estradiol